Drugs / V710
V710
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT00735839 | Mar → Jun 2008 | staphylococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00822757 | Aug → Oct 2007 | — | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01324440 | Sep 2006 → Oct 2007 | staphylococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00303069 | Nov 2005 → Jul 2006 | staphylococcal infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00572910 | Aug 2008 → Jan 2010 | staphylococcus aureus infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT00518687 | Dec 2007 → Aug 2011 | mediastinitis, staphylococcus aureus infection | Merck Sharp & Dohme LLC | Terminated | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V710 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00518687 ↗ |
| Known as | Merck S. Aureus Vaccine | “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male...” NCT00735839 ↗ |
| Known as | Merck V710 | “Merck V710 is a novel vaccine containing the conserved Staphylococcus aureus iron surface determinant B shown to be protective in animal models.” PMID 20943877 ↗ Oct 20101“Merck V710 is a novel vaccine that contains the highly conserved Staphylococcus aureus iron surface determinant B (IsdB) protein.” PMID 22192849 ↗ Dec 2011 |
| Modality | Vaccine | “Merck V710 is a novel vaccine containing the conserved Staphylococcus aureus iron surface determinant B shown to be protective in animal models.” PMID 20943877 ↗ Oct 2010 |
| Route | Intramuscular | “Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly” NCT00303069 ↗ |